Last checked at 10 Jun 2016 14:04
MaxCyte, Inc.
("MaxCyte" or the "Company")
Publication of Annual Report and Notification of AGM
Maryland, USA - 10 June 2016: MaxCyte (LSE: MXCT), the developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, gives notice that its Annual Report and Accounts for the year ended 31 December 2015 ("Annual Report") has been published on the "Investors" section of the Company's website at www.maxcyte.com.
MaxCyte announced preliminary results for the year ended 31 December 2015 on 10 May 2016, and expects to post printed copies of the Annual Report to stockholders in the Company ("Stockholders") shortly.
Further copies of the Annual Report will be available from the Company Secretary, MaxCyte, Inc., 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878, USA.
MaxCyte also announces that its Annual General Meeting of Stockholders is planned to be held on 26 October 2016 at 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878 USA. Formal notice and resolutions, along with the Annual Meeting Proxy Card, will be circulated on or about 1 September 2016 to Stockholders of record on or about that date.
For further information please contact:
MaxCyte | +1 301 944 1660 |
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer | |
Nominated Adviser and Broker Panmure Gordon Freddy Crossley (Corporate Finance) Fabien Holler Duncan Monteith Tom Salvesen (Corporate Broking) | +44 (0) 20 7886 2500
|
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700 maxcyte@consilium-comms.com |
Mary-Jane Elliott Chris Welsh Lindsey Neville |
About MaxCyte
MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of cell-based medicines.
MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, commercial and clinical grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers with an established regulatory path.
MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies in a number of cancer indications, including solid tumors.
For more information visit http://www.maxcyte.com/